The landscape of Alzheimer’s disease (AD) research and treatment is undergoing a significant transformation, marked by the recent advent of disease-modifying therapies (DMTs) and the development of accessible blood-based biomarker tests. These milestones, celebrated and dissected at the 2026 Alzheimer’s Association International Conference (AAIC) in London, have ignited optimism for revolutionizing patient care. However, the conference also underscored persistent challenges, particularly the need for a deeper understanding of Alzheimer’s subtypes, the optimization of treatment strategies, and the critical imperative of ensuring equitable access to diagnostic tools and emerging therapies across diverse global populations.
Held from July 12-15, 2026, the AAIC served as a crucial platform for leading scientists, clinicians, and industry stakeholders to convene and deliberate on the trajectory of Alzheimer’s research. In the wake of groundbreaking regulatory approvals, the discussions at AAIC 2026 shifted towards unpacking the implications of these advancements and charting a course for future R&D, treatment, and care. Key themes that dominated the agenda included the increasing recognition of Alzheimer’s heterogeneity through the identification of distinct disease subtypes, the pivotal role of biomarkers in early diagnosis and monitoring, the urgent necessity of incorporating diversity into research, and the strategic optimization of therapeutic approaches.
Unraveling Alzheimer’s Heterogeneity: The Promise of Subtype Identification
For over a century, Alzheimer’s disease was largely conceptualized as a singular entity, a neurodegenerative condition first identified by German psychiatrist and neuropathologist Dr. Alois Alzheimer in 1906. However, accumulating research has revealed a profound complexity within the disease, characterized by significant variations in patient symptoms, rates of progression, and long-term outcomes. This growing understanding has fueled a compelling question: are there more precise ways to categorize and address the diverse manifestations of Alzheimer’s?
A pivotal contribution to this evolving understanding came from Dr. Betty Tijms, an associate professor at the Alzheimer Center in Amsterdam. Presenting at a plenary session, Dr. Tijms challenged the monolithic view of Alzheimer’s, proposing through extensive proteomic and metabolomic analysis of spinal fluid samples that the disease may, in fact, encompass at least five distinct subtypes. These proposed subtypes are believed to be driven by differing underlying biological mechanisms, including neuronal hyperplasticity, the innate immune response, and impairments in the blood-brain barrier.
Dr. Tijms theorizes that this biological heterogeneity could be a significant factor contributing to the failure of certain therapies in clinical trials. If a treatment is not tailored to the specific biological underpinnings of a particular subtype, its efficacy may be diminished or entirely absent in a broader patient population. Conversely, the identification of these subtypes could illuminate novel therapeutic targets beyond the traditional focus on amyloid and tau pathology, opening new avenues for drug development.
The implications of Dr. Tijms’ theory are far-reaching for Alzheimer’s drug development. It suggests a potential future where subtype-specific biomarkers are essential for accurate diagnosis, and tailored therapeutics are developed to address the unique biological drivers of each subtype. Furthermore, the increased reliance on proteomic analysis of cerebrospinal fluid (CSF) could become a critical tool for precisely diagnosing and treating patients.
Samuel Dickson, SVP of statistics at biostatistics consultancy firm Pentara, acknowledged this shift, noting that some pharmaceutical sponsors are beginning to adapt their development strategies to account for subtypes. However, he cautioned that such an approach is contingent on the specific therapeutic mechanism being investigated. "Heterogeneity is a fact of life," Dickson stated in an interview with Pharmaceutical Technology. "You have to have pretty clear delineation to say ‘we’re going to rule out this entire subpopulation’ because you’ll be dealing with larger screen fail rates and costs, so the benefit to a trial has to be clear if you’re going to deal with the heterogeneity."
Francesca Capotosti, SVP of research at AC Immune, a company actively developing a range of Alzheimer’s therapies targeting pathological tau, neuroinflammation, and misfolded amyloid-beta, echoed this sentiment. She suggested that patient subclassification is likely the future direction of the field, though widespread implementation is still in its nascent stages due to the early phase of this research.
Biomarkers Advance, But Imaging Accessibility Remains a Hurdle
Concurrent with the discussions on disease characterization, the burgeoning role of biomarkers in Alzheimer’s diagnosis and management was a prominent topic at AAIC 2026. Blood-based tests capable of detecting key disease indicators, such as phosphorylated tau (p-tau217), are increasingly being hailed as the next frontier in making research and care more accessible.
Christopher Weber, director of global science initiatives at the Alzheimer’s Association, previously highlighted to Pharmaceutical Technology that non-invasive screening methods, including digital biomarkers and blood tests, hold the potential to bridge the gap between primary and specialized neurology care. This is particularly critical given the persistent shortage of memory specialists and the fact that primary care physicians remain the initial point of contact for most patients.
However, concerns regarding the socioeconomics of Alzheimer’s disease and the accessibility of diagnostic tools were repeatedly raised by researchers. Even blood-based biomarkers, which are generally considered more affordable and accessible than imaging techniques like MRI or amyloid PET scans, face significant barriers. Dr. Elisa de Paula França Resende, a Brazilian neurologist, highlighted during a session on implementing anti-amyloid therapies in real-world settings that access to spinal fluid and plasma biomarker tests is severely limited in Latin America. The absence of public coverage in many regions necessitates out-of-pocket expenses for patients, creating a substantial financial burden.
This accessibility gap is further exacerbated by the lack of preparedness across global healthcare systems, a point emphasized by both Dr. Resende and Professor Jonathan Schott of University College London (UCL). Professor Schott noted in his presentation that testing infrastructure in Europe requires substantial bolstering to accommodate the anticipated increase in demand driven by early imaging and the ongoing monitoring requirements associated with anti-amyloid therapies.
Suchandrima Banerjee, general manager of the neurology care pathway at GE Healthcare, pointed out the recent introduction of novel biomarkers that can be integrated into the screening and triage process, complementing established methods like MRI and PET scans. "We see these approaches as complementary because Alzheimer’s is a population-level disease," Banerjee remarked. She advocated for the development of a diverse array of screening and triaging tools to assist healthcare systems in identifying patients who are likely to have Alzheimer’s, thereby enabling more targeted confirmatory diagnoses through tools like amyloid PET. GE Healthcare has been actively developing digital tools to optimize imaging processes and provides essential imaging machinery, including MRI, PET/MR, and PET/CT scanners, for screening purposes.
Championing Diversity for Robust Research and Improved Outcomes
A critical and pervasive theme at AAIC 2026 was the imperative of equal inclusion in Alzheimer’s research. Experts sounded a strong warning that the persistent lack of diversity within clinical trials risks compromising the ethical integrity, scientific validity, and real-world applicability of both clinical and post-marketing studies.
A dedicated panel discussion underscored that diversity and inclusion in trials are not merely desirable but essential. To achieve this, researchers advocated for a community-first approach, emphasizing the importance of involving patient communities in the co-development process and meticulously considering specific cultural needs during the research design phase.
Klaus Dugi, CEO of biotech company Vandria, which is developing a drug for Alzheimer’s and other conditions, shared the company’s strategy to enhance diversity. Vandria is conducting a smaller, yet more broadly inclusive trial for its investigational drug, VNA-318. By carefully assessing patient characteristics, biomarkers, and cognitive parameters, the company aims to determine if specific subpopulations might derive greater benefit from the therapy. "In the first study, we don’t want to restrict the patient population too much – we want to learn if there’s a group that may accrue a particularly high benefit, such as patients with two copies of the APOE4 gene, as we have preclinical data suggesting that they may benefit especially," Dugi explained.
Neil Warma, CEO of ProMIS Neurosciences, a company developing an Alzheimer’s therapy targeting toxic amyloid oligomers, posited that artificial intelligence (AI) for trial design and computational models for real-world evidence (RWE) generation will play a pivotal role in advancing the field concerning accessibility and diversity.
Optimizing Treatment Strategies for Enhanced Patient Outcomes
As disease-modifying anti-amyloid therapies, such as Biogen and Eisai’s Leqembi (lecanemab) and Eli Lilly’s Donanemab, become increasingly integrated into the Alzheimer’s treatment paradigm, pharmaceutical companies and researchers are actively seeking ways to further enhance patient outcomes. This pursuit involves not only the development of novel medications but also the optimization of the utilization of currently available therapeutic tools.
A widely discussed strategy at AAIC 2026 was the adoption of combination therapeutic approaches, a sentiment echoed by Francesca Capotosti, Neil Warma, and Klaus Dugi. This could involve pairing anti-amyloid drugs with different mechanisms of action, as well as combining them with tau-targeting therapies, such as Biogen’s diranersen, and modulators of neuroinflammation. During the conference, several researchers, alongside Dugi and Capotosti, highlighted the significant potential of mitigating neuroinflammation as a key therapeutic strategy in Alzheimer’s disease.
Pharmaceutical companies are also exploring the application of anti-amyloid treatments in earlier stages of the disease. Roche announced at AAIC 2026 the initiation of a Phase III study, named PrevenTRON, for its late-stage Alzheimer’s candidate, trontinemab. This decision is underpinned by emerging research suggesting that the removal of amyloid plaques in the preclinical stages of Alzheimer’s, before significant cognitive decline occurs, could lead to improved care and long-term patient benefits.
Despite these promising advancements, experts at the conference consistently emphasized the paramount importance of early diagnosis. They underscored that timely and accurate diagnosis is crucial for unlocking the full therapeutic potential of emerging treatments, particularly as current therapeutic options are primarily designed for patients in the early stages of the disease. Without early intervention, the window of opportunity for these life-altering therapies may be significantly narrowed, limiting their overall impact on disease progression and patient quality of life. The integration of advanced diagnostic tools, coupled with a deeper understanding of disease subtypes and a commitment to equitable access, will be critical in navigating the complex path toward effectively managing and ultimately conquering Alzheimer’s disease.
